Leadership

We’re Delivering the Promise of Healthier Lives.

Executive Team Members

Robert Davidson

CEO 

Robert Davidson is CURE’s CEO and creator of the technology. Prior to his role at CURE Davidson served as President and Chief Executive Officer of InnoZen Inc., Chief Executive Officer of Gel Tech LLC, Chief Executive Officer of Bio Delivery Technologies Inc., and has served on multiple corporate boards. Davidson was responsible for the development of several drug delivery technologies and commercial brand extensions. He has worked with brands such as Chloraseptic™, Suppress™, as well as Pediastrip™, a private label electrolyte oral thin film sold in major drug store chains. Davidson received his B.S. degree with a concentration in Biological Life Sciences. He holds a Masters Certificate in Applied Project Management from Villanova University, a Masters of Public Health from American Military University, Virginia and a Masters in Health and Wellness from Liberty University, Virginia. Davidson also completed his Post Graduate Studies and Masters degree at the University of Cambridge with letter of commendation.

Mark Udell

Chief Financial Officer

Mark Udell currently serves as our Chief Financial Officer and previously served as our Chief Accounting Officer. Prior to that, Mark served as Chief Accounting Officer of CURE Pharmaceutical Holding Corp (“CPHC”) from 2018 until 2022 where he was an integral part of selling the pharmaceutical assets of CPHC for $20 million. From 2011 until 2018 Mark served as the Chief Financial Officer of Cure Pharmaceutical Corporation (“CPC”) where he was responsible for all public Securities and Exchange Commission filings, financial audits, accounting and assisted with financing transactions. From 2007 to 2011, he served as Chief Accounting Officer and Controller of InnoZen, Inc., another drug delivery company, where he was responsible for establishing, monitoring, and enforcing internal policies and procedures, as well as conducting audits and working with external auditors. Prior to Mark’s time at InnoZen, he served as Auditing Manager at Green Hasson & Janks, LLP in Los Angeles. Mark is a Certified Public Accountant with over 24 years of experience in finance and accounting and has gained valuable knowledge in the drug delivery industry during his time at CPHC, CPC and InnoZen. He is a key contributor to our development, operations and commercialization of various drug delivery technologies. He holds a B.S. in Business Economics with a concentration in accounting from the University of California, Santa Barbara.

Patricia Hess

Chief Operating Officer

Patricia Hess is the Chief Operating Officer of CURE. She is responsible for ensuring our operational structure is poised to drive CURE’s strategic priorities while enabling a culture of teamwork and collaboration. She brings 2 decades of leadership experience in the biopharmaceutical sector leading talent strategy and operations for industry leaders. While at Amgen, she held human resources roles of increasing responsibility and led large scale multi-national teams and programs covering the areas of the Americas, Europe and Asia Pacific. At Kite Pharma (acquired by Gilead Sciences) Patricia was Global Head of Talent and was responsible for expansive talent growth following FDA and EMA approval for novel CAR T cell therapy. Patricia hired, led, and developed a high performing global team leading the talent expansion in US, Europe and Asia Pacific. Patricia developed operating plans and metrics to ensure an optimal operating structure to include strategic internal and external partnerships to deliver a consistent, reliable scalable workforce. Patricia attended Liberty University in the Leadership Cognate.